Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells

American Journal of Kidney Diseases

Volumn 36, Issue 6, 2000, Pages 1242-1252

  Amore, Alessandro ^a,b   Conti, Giovanni ^a,b   Cirina, Paola ^a,b   Peruzzi, Licia ^a,b   Alpa, Mirella ^a,b   Bussolino, Federico ^a,b   Coppo, Rosanna ^a,b  

^a Regina Margherita Hospital   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Abnormally glycosylated immunoglobulin A (IgA); Degalactosylated immunoglobulin A (deGal IgA); Desialylated immunoglobulin A (deSia IgA); Immunoglobulin A (IgA) nephropathy; Mesangial cells (MCs); Nitric oxide (NO); Vascular endothelial growth factor (VEGF)

Indexed keywords

IMMUNOGLOBULIN A; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; MESANGIUM CELL; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS; SCLEROSIS; TISSUE REPAIR;

EID: 0033659379     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.19840     Document Type: Article

References (45)

1. The glomerular response to injury: Progression or resolution?
2. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis
3. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor
4. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
5. The biology of vascular endothelial growth factor
6. Role of vascular endothelial growth factor in the regulation of angiogenesis
7. Biological properties of VEGF-A/VPF receptors
8. Renal microvascular assembly and repair: Power and promise of molecular definition
9. Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis
10. Vascular permeability factor mRNA and protein expression in human kidney
11. Expression of vascular permeability factor (VPF/VEGF-A) is altered in many glomerular diseases
12. Expression of vascular endothelial growth factor in renal vascular disease and renal allograft
13. Angiogenesis and vascular endothelial growth factor (VEGF-A): Is it relevant in renal patients?
14. Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis
15. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide dependent hypotension
16. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
17. Nitric oxide mediates angiogenesis induced in vivo by platelet activating factor and tumor necrosis factor-α
18. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced anglogenesis
19. VEGF upregulates cNOS message, protein, and NO production in human endothelial cells
20. Role of VEGF-A receptor-1 in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells
21. Increased gene expression for VEGF-A and the VEGF-A receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia
22. Production of vascular endothelial growth factor by murine macrophages: Regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway
23. Differential regulation of vascular endothelial growth factor and its receptor fms-like tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells
24. Nitric oxide: Pathophysiological mechanisms
25. Nitric oxide: Cytotoxicity versus cytoprotection - How, why, when and where?
26. Pathogenesis of IgA nephropathy: Established observations, new insight and perspectives in treatment
27. Gluten-induced experimental IgA
28. IgA antibodies to dietary antigens and lectin-binding IgA in sera from Italian, Australian and Japanese IgA nephropathy patients
29. Cytokine mRNA expression by cultured rat mesangial cells after contact with environmental lectins
30. Serum IgA and macromolecular IgA reacting with mesangial matrix components
31. Functional consequences of the binding to gliadin of cultured rat mesangial cells: Bridging immunoglobulin A to cells and modulation of eicosanoids synthesis and altered cytokine production
32. Macromolecular IgA and abnormal IgA reactivity in sera from children with IgA nephropathy
33. IgA serology in recurrent and non-recurrent IgA nephropathy after renal transplantation
34. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy
35. Association of asialogalactosyl β1-3N-acetylgalactosamine on the hinge with a conformational instability of jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy
36. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG
37. Leukocyte beta 1,3 galactosyltransferase activity in IgA nephropathy
38. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines
39. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix Proteins
40. The sialic acids: VI purification Properties of sialidase from Clostridium perfrigens
41. The purification and properties of β galactosidase from bovine testes
42. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction
43. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting. Implications for measurement of circulating VEGF levels in clinical disease
44. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis
45. Mammalian nitric oxide synthases